Re: Prediction: On thursday, Didier Rouy's presentation will reveal two additional Golden Patients...
"a PR on SB-525 to mark the close of P2"... the company's recent slide presentations noted that the P2 enrollment is complete... but it won't "close" for a while... the trial design provides for 3 years of follow-up after dosing.
and Rouy was a participant at ISTH in early July when the data cut-off date was 5/30... that data is now more than 2.5 months old, there's only 5 patients in cohort 4, and it's definitely ripe for an update... if no update, they're just shooting themselves in the foot again.
SM was adamant that only PFE can speak to P3... but shame on him if SGMO doesn't continue to trumpet P2 progress on a timely basis.